Last reviewed · How we verify
Serratus
Serratus, marketed by Memorial Sloan Kettering Cancer Center, holds a niche position in the oncology market with its unique mechanism of action. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the lack of detailed revenue data and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Serratus |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Drug class | Non-Standardized Animal Skin Allergenic Extract [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome (PHASE2)
- Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block for Analgesia in Arthroscopic Shoulder Surgery (NA)
- SPSIPB vs CCB in Arthroscopic Shoulder Surgeries (NA)
- Comparison of the Analgesic Efficacy of Chest Wall Blocks in Coronary Artery Bypass Surgery (NA)
- Scapular Muscle Strengthening Combined With Core Stabilization Exercises in Telephone Operators With Neck Pain (NA)
- Effects of Kinetic Chain Exercises on Pain, Range of Motion and Disability in Shoulder Impingement Syndrome (NA)
- Efficacy of Adding Early Scapular Muscles Strengthening Exercise After Rotator Cuff Repair on Scapula Kinematics (NA)
- Shoulder Exercise Training on Pain, Range of Motion, and Functional Limitations in Women Following Unilateral Mastectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |